Biogen Inc (BIIB)
221.69
-1.18
(-0.53%)
USD |
NASDAQ |
May 10, 16:00
221.69
0.00 (0.00%)
After-Hours: 20:00
Biogen Cash from Financing (TTM): -246.90M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -246.90M |
| December 31, 2023 | 149.30M |
| September 30, 2023 | 788.00M |
| June 30, 2023 | -1.312B |
| March 31, 2023 | -1.774B |
| December 31, 2022 | -1.747B |
| September 30, 2022 | -1.730B |
| June 30, 2022 | -1.225B |
| March 31, 2022 | -1.318B |
| December 31, 2021 | -2.086B |
| September 30, 2021 | -2.497B |
| June 30, 2021 | -3.064B |
| March 31, 2021 | -3.812B |
| December 31, 2020 | -5.273B |
| September 30, 2020 | -6.988B |
| June 30, 2020 | -6.364B |
| March 31, 2020 | -7.426B |
| December 31, 2019 | -5.860B |
| September 30, 2019 | -5.181B |
| June 30, 2019 | -4.467B |
| March 31, 2019 | -4.883B |
| December 31, 2018 | -4.472B |
| September 30, 2018 | -3.743B |
| June 30, 2018 | -3.788B |
| March 31, 2018 | -1.747B |
| Date | Value |
|---|---|
| December 31, 2017 | -2.38B |
| September 30, 2017 | -2.398B |
| June 30, 2017 | -2.684B |
| March 31, 2017 | -1.949B |
| December 31, 2016 | -1.053B |
| September 30, 2016 | -2.528B |
| June 30, 2016 | 685.10M |
| March 31, 2016 | 697.30M |
| December 31, 2015 | 783.10M |
| September 30, 2015 | 2.472B |
| June 30, 2015 | -471.22M |
| March 31, 2015 | -789.98M |
| December 31, 2014 | -755.90M |
| September 30, 2014 | -231.40M |
| June 30, 2014 | -514.80M |
| March 31, 2014 | -363.20M |
| December 31, 2013 | -716.50M |
| September 30, 2013 | -743.23M |
| June 30, 2013 | -452.96M |
| March 31, 2013 | -699.64M |
| December 31, 2012 | -877.48M |
| September 30, 2012 | -1.005B |
| June 30, 2012 | -1.076B |
| March 31, 2012 | -636.29M |
| December 31, 2011 | -319.86M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-7.426B
Minimum
Mar 2020
788.00M
Maximum
Sep 2023
-3.072B
Average
-2.292B
Median
Cash from Financing (TTM) Benchmarks
| Eli Lilly and Co | 2.772B |
| Bristol-Myers Squibb Co | 8.278B |
| Gilead Sciences Inc | -5.08B |
| AbbVie Inc | -211.00M |
| Sage Therapeutics Inc | 4.912M |